Related Experiment Video
Updated: Jan 31, 2026

Murine Echocardiography of Left Atrium, Aorta, and Pulmonary Artery
Published on: February 20, 2017
Biomechanical characterization of murine pulmonary arteries
Abhay B Ramachandra1, Jay D Humphrey2
1Department of Biomedical Engineering, Yale University, New Haven, CT, United States.
Abstract:
The biomechanical properties of the major pulmonary arteries play critical roles in normal physiology as well as in diverse pathophysiologies and clinical interventions. Importantly, advances in medical imaging enable simulations of pulmonary hemodynamics, but such models cannot reach their full potential until they are informed with region-specific material properties. In this paper, we present passive and active biaxial biomechanical data for the right and left main pulmonary arteries from wild-type mice. We also evaluate the suitability of a four-fiber family constitutive model as a descriptor of the passive behavior. Despite regional differences in size, the biaxial mechanical properties, including passive stiffness and elastic energy storage, the biaxial wall stresses at in vivo pressures, and the overall contractile capacity in response to smooth muscle cell stimulation under in vivo conditions are remarkably similar between the right and left branches. The proposed methods and results can serve as baseline protocols and measurements for future biaxial experiments on murine models of pulmonary pathologies, and the constitutive model can inform computational models of normal pulmonary growth and remodeling. Our use of consistent experimental protocols and data analyses can also facilitate comparative studies in health and disease across the systemic and pulmonary circulations as well as studies seeking to understand remodeling in surgeries such as the Fontan procedure, which involves different types of vessels.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...

